Based upon our results in this large, well-characterized population-based cohort, stage II and III CRC patients with low levels of IGFBP3 promoter methylation had poorer OS and DFS compared to those with high levels of DNA hypermethylation. Here, IGFBP3 is linked to colorectal carcinoma.